XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Total
CRMS
FMC NA
Healthwrox
Additional Paid-in- Capital
Additional Paid-in- Capital
CRMS
Additional Paid-in- Capital
FMC NA
Accumulated Deficit
Accumulated Deficit
FMC NA
Accumulated Other Comprehensive (Loss) Income
Noncontrolling Interests
Noncontrolling Interests
FMC NA
Noncontrolling Interests
Healthwrox
Series A
Preferred Stock
Class A
Common Stock
Class A
Common Stock
CRMS
Class A
Common Stock
FMC NA
Class B
Common Stock
Beginning balance (in shares) at Dec. 31, 2020                           28,055        
Beginning balance at Dec. 31, 2020 $ 66,947,041       $ 142,346,852     $ (87,300,472)   $ (48,539) $ 11,949,200     $ 0 $ 0     $ 0
Beginning balance (in shares) at Dec. 31, 2020                             35,497     55,008
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Effect of reverse acquisition (in Shares)                           18,099,548 22,900,719     35,488,938
Conversion of share due to merger recapitalization (in Shares)                           (18,099,548) (22,900,719)     (35,488,938)
Conversion of share due to merger recapitalization 7,649                           $ 7,649      
Effect of reverse acquisition (in shares)                             76,489,205      
Effect of reverse acquisition 66,954,690       142,346,852     (87,300,472)   (48,539) 11,949,200       $ 7,649      
Share issued for services (in Shares)                             171,608      
Share issued for services 17                           $ 17      
Exercise of cashless warrants (in Shares)                             1,817,507      
Exercise of cashless warrants 182                           $ 182      
Issuance of shares net redemption and issuance costs (in Shares)                             5,297,097      
Issuance of shares net redemption and issuance costs 43,405,088       43,404,558                   $ 530      
Acquisitions (in shares)                             12,500,000      
Acquisitions 114,603,568       114,602,318                   $ 1,250      
Exercise of stock options (in Shares)                             1,235,131      
Exercise of stock options 628,592       628,469                   $ 123      
Stock-based compensation 1,376,353       1,376,353                          
Fair value of Warrants from reverse acquisition (18,717,998)       (18,717,998)                          
U.K. Ltd. Shares purchase (in Shares)                             50,192      
UK Ltd. Shares purchase (722,276)       (479,336)           (242,945)       $ 5      
Sponsor Earnout shares (in Shares)                             2,573,213      
Sponsor Earnout shares 257                           $ 257      
Noncontrolling interest contribution 333,025                   333,025              
Foreign currency translation 16,038                 16,038                
Net loss attributable to noncontrolling interests (4,564,270)                   (4,564,270)              
Net income attributable to stockholders of DocGo Inc. and Subsidiaries 23,743,758             23,743,758                    
Ending balance (in shares) at Dec. 31, 2021                           0        
Ending balance at Dec. 31, 2021 227,057,024       283,161,216     (63,556,714)   (32,501) 7,475,010     $ 0 $ 10,013     $ 0
Ending balance (in shares) at Dec. 31, 2021                             100,133,953     0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Equity cost (19,570)       (19,570)                          
Common stock repurchased (in shares)                             (536,839)      
Common stock repurchased $ (3,731,712)       (3,731,658)                   $ (54)      
Exercise of stock options (in Shares) 1,699,720                           1,053,401      
Exercise of stock options $ 1,980,779       1,980,674                   $ 105      
Cashless exercise of options (in shares)                             354,276      
Cashless exercise of options (194)       (230)                   $ 36      
Stock-based compensation 7,183,992       7,183,992                          
Restricted stock units 495,579       495,579                          
Share warrants conversion (in Shares)                             1,406,371      
Share warrants conversion 12,381,573       12,381,432                   $ 141      
Noncontrolling interest contribution 2,063,000                   2,063,000              
Foreign currency translation 773,707                 773,707                
Net loss attributable to noncontrolling interests (3,841,285)                   (3,841,285)              
Net income attributable to stockholders of DocGo Inc. and Subsidiaries 34,584,498             34,584,498                    
Ending balance (in shares) at Dec. 31, 2022                           0        
Ending balance at Dec. 31, 2022 $ 278,927,391       301,451,435     (28,972,216)   741,206 5,696,725     $ 0 $ 10,241     $ 0
Ending balance (in shares) at Dec. 31, 2022 102,411,162                           102,411,162     0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
UK Ltd. restricted stock $ 167,175       167,175                          
Health liquidation $ 70,284             70,284                    
Acquisitions (in shares)                               117,330 360,145  
Acquisitions   $ 1,000,012       $ 1,000,000 $ (1,432,963)   $ 649,167             $ 12 $ 36  
Purchase of interests     $ (3,997,716) $ (1,296,553)               $ (3,213,956) $ (1,296,553)          
Exercise of stock options (in Shares) 514,065                           465,429      
Exercise of stock options $ 1,414,008       1,413,962                   $ 46      
Cashless exercise of options (in shares)                             6,374      
Cashless exercise of options 0       (1)                   $ 1      
Shares withheld for taxes (in shares)                             (280,654)      
Shares withheld for taxes (2,308,954)       (2,308,927)                   $ (27)      
Stock bases compensation (in shares)                             975,382      
Stock-based compensation 20,403,282       20,403,185                   $ 97      
Foreign currency translation 743,699                 743,699                
Net loss attributable to noncontrolling interests 3,189,873                   3,189,873              
Net income attributable to stockholders of DocGo Inc. and Subsidiaries 6,858,455             6,858,455                    
Ending balance (in shares) at Dec. 31, 2023                           0        
Ending balance at Dec. 31, 2023 $ 305,170,956       $ 320,693,866     $ (21,394,310)   $ 1,484,905 $ 4,376,089     $ 0 $ 10,406     $ 0
Ending balance (in shares) at Dec. 31, 2023 104,055,168                           104,055,168     0